TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Early Behavioral Intervention for Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infant is a singleton (matched between groups)~* Mother is 18 years of age or older~* Mother has at least one supporting person in the home (e.g. significant other, mother, father, sibling, aunt, grandmother, step-parent)~* Child demonstrates developmental deficit (language, cognition, motor, emotion)~Exclusion Criteria:~* The child has severe congenital anomalies including chromosomal anomalies~* The child has severe motor or physical disability~* Mother currently presents with psychosis or is currently taking antipsychotic medication~* Status of enrolled subject changes and subject no longer falls in inclusion criteria~* Mother and/or infant has a medical condition that precludes intervention components~* Mother and/or infant has a contagion that endangers other participants in the study

- Gender: ALL
- Minimum Age: 30 Months
- Maximum Age: 40 Months
- Healthy Volunteers: t

Study Arms:
- Family Nurture Intervention Group (Type: EXPERIMENTAL): Children in the FNI group will continue to attend any intervention programs that they are already enrolled in. In addition, they will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks. During each visit, the mother-child will meet with trained Nurture Specialists. The Nurture Specialists will facilitate and encourage the mother and child to engage in nurturing and calming activities, including sustained touch, vocal soothing, and an odor cloth exchange. FNI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.
- Play and Nutrition Intervention Group (Type: ACTIVE_COMPARATOR): Children in the PNI group will continue to attend any intervention programs that they are already enrolled in. They will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks to meet with clinical personnel who will collect measures regarding the child's behavior and development. At each visit, study staff will meet with mothers to facilitate a lesson plan on appropriate play and nutrition. NPI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Enteral Feeding Study of Formula Containing Fish Oil in Critical Care Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 - 70 years old~* New ICU admit~* Enteral tube feeding anticipated for at least 7 days~* Informed consent~Exclusion Criteria:~* Enteral tube feeding immediately prior to admit~* Parenteral feeding~* Medical condition that preclude receiving tube feeding or formula~* Determined by PI to be inappropriate~* Participating in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Influence of a Warmed Surgical Bandage System on Subcutaneous Tissue Oxygen Tension After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥18 years of age scheduled for elective cardiac surgery on normothermic cardio-pulmonary bypass will be invited to participate~Exclusion Criteria:~* Emergency surgery~* Pre - or postoperative on intraaortic balloon pump~* Preoperative mechanical ventilation~* Postoperative respiratory failure~* Postoperative extracorporal membrane oxygenation~* Left ventricular function \< 40%~* Fever (core temperature \> 38 °C) or current infection~* No anticipated or no definitive primary closure of surgical wound.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- conventional bandage (Type: ACTIVE_COMPARATOR): conventional bandage on sternal wound after skin closure after cardiac surgery. conventional gauze covered with elastic adhesive (Medipore™ Dress-it) The designated bandage will be positioned in the operating room by the surgeons after the skin will be closed. The conventional elastic bandage consists of several layers of gauze covered with a special adhesive bandage
- warming bandage (Type: ACTIVE_COMPARATOR): The Warm-Up bandage consists of an adhesive shell and a foam frame that supports a clear window about one cm above the surface of the wound. A battery-powered heating card can then be inserted into the window to provide gentle warming of the wound. The surface temperature of heating card is fixed at 38°C, and heat is usually provided for two hours at a time. That is, the experimental bandage will be continuously applied to the wound and heated to 38°C using a two-hour on/off cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect and Utilization of Protected Time Among Interns on Extended Duty-Hour Call Shifts

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Interns in the Providence St. Vincent Medical Center Internal Medicine Residency Program who are rotating through the medical intensive care unit.~Exclusion Criteria:~* Refusal to consent to participate

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Protected Time Group (Type: EXPERIMENTAL): Interns working 30 hour shifts every 3rd night and an average of 80 hours per week in a medical intensive care unit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ductal adenocarcinoma~2. Age ≥20 and ≤80~3. General performance status: the Karnofsky score\> 70% or ECOG 0-1~4. Potentially Curative resection~5. Tumor size \< 3cm~6. Pancreatic cancer located on neck or body portion~7. No invasion to spleen or spleen hilum~8. No combined resection except Lt. adrenal gland~9. Distance more than 5cm (≥5cm) between tumor lateral margin and spleen hilum~Exclusion Criteria:~1. Unresectable or locally advanced, metastatic case~2. Patients who do not want surgery~3. ASA (American society of anesthesiologists' physical status classification) score: ≥3~4. Patients with drug or alcohol addiction~5. Patients showing low compliance~6. Patients who not want to involve the clinical trial~7. Patients who are unable to read or understand the informed consent, sign a consent form (eg, mental retardation, blindness, illiteracy, foreign, etc.)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- RAMPS (Type: EXPERIMENTAL): Radical Antegrade Modular Pancreatectomy with Splenectomy
- RAMP (Type: ACTIVE_COMPARATOR): Radical Antegrade Modular Pancreatectomy without splenectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diabetic Retinopathy and Subclinical Signs of Disease Transition

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diabetes mellitus type 1 or 2~* Age 18-90~Exclusion Criteria:~* Media opacities like cataract or vitreous hemorrhage~* Active intraocular inflammation (grade trace or above) in either eye like infectious conjunctivitis, keratitis, scleritis, endophthalmitis as well as idiopathic or autoimmune-associated uveitis in either eye~* Structural damage to the center of macula in the study eye~* Atrophy of retinal pigment epithelium, subretinal fibrosis, laser scar within foveal avascular zone (FAZ) or organized hard exudate plaques~* Ocular disorders in the study eye including retinal vascular occlusion, retinal detachment, macular hole, choroidal neovascularization, macula dystrophies~* Intraocular surgery (including cataract surgery, YAG laser capsulotomy) in the study eye within 3 months preceding Day 0, or history of corneal transplantation in the study eye~* Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma medication)or history of glaucoma filtration surgery~* Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality to be analyzed and graded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Intensified blood glucose control (Type: None): Patients with diabetes mellitus type 2 and poor blood sugar control that are introduced to insulin or GLP-1 therapy
- Nephropathy (Type: None): Patients that are introduced to hemodialysis or renal transplantation secondary to renal failure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Have coronary artery disease and clinical indication for percutaneous coronary intervention (PCI) with implantation of at least one drug-eluting stent and where percutaneous coronary intervention of all treated lesions is successful.~* Have been given standard-of-care clopidogrel 600-mg loading dose between 24 hours before and at the time of PCI.~* Standard of Care Aspirin use prior to PCI - at least 250-mg \[intravenous (IV) or oral\] within 24 hours before PCI and at the time of PCI.~* VerifyNow P2Y12 reaction units \> 208 measured 2-7 hours after clopidogrel maintenance dose the day after successful PCI.~Exclusion Criteria:~* Non-ST segment elevation myocardial infarction within 14 days prior to randomization~* ST-segment elevation myocardial infarction within 14 days prior to randomization~* Have known major complications after percutaneous coronary intervention and prior to randomization~* Have a body weight \< 60 kilogram (kg)~* Have cardiogenic shock at time of randomization~* Have refractory ventricular arrhythmias~* Have New York Heart Association Class IV congestive heart failure~* Have received glycoprotein (GP) IIb/IIIa inhibitors eptifibatide or tirofiban within 24 hrs before or during percutaneous coronary intervention or abciximab within 10 days before or during percutaneous coronary intervention~* Are receiving daily treatment with nonsteroidal anti-inflammatory drug (NSAIDs) or cyclooxygenase-2 (COX2) inhibitors that cannot be discontinued or are anticipated to require \> 2 weeks of daily treatment during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: EXPERIMENTAL): None
- Clopidogrel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of cystic fibrosis confirmed by mutation analysis of the cystic fibrosis transmembrane conductance regulator gene~* Sputum or throat swab culture positive for Pseudomonas aeruginosa at or within 6 months of enrollment~* Age ≥12 years~* Forced expiratory volume in one second (FEV1) 25-90 percent-predicted~Exclusion Criteria:~* Age \<18 years~* Inability to routinely expectorate sputum without induction by hypertonic saline~* Inability to provide or withdrawal of written informed consent~* History of aminoglycoside sensitivity or adverse reaction to inhaled antibiotics~* Serum creatinine ≥ 2.0 mg/dl~* Serum blood urea nitrogen (BUN) ≥40 mg/dl~* Pregnancy or lactating at screening~* History of systemic intravenous anti-Pseudomonal antibiotics within 28 days of enrollment

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Continuous Therapy (Type: None): TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day cycle colistimethate 75 mg inhaled two times daily. Repeat cycle.
- Cyclic therapy (Type: None): TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day period during which no inhaled antibiotics are used. Repeat cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intraocular Pressure (IOP) Changes Associated With Muslim Prayer Postural Changes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with primary open angle glaucoma~* Must be age 18 and up~* Provide written informed consent to participate~* Able to cooperate with ocular examination for 60-90 minutes~* Able to assume the standing, bowing, and prostrate positions~Exclusion Criteria:~* Special patient populations (children, pregnant women, prisoners etc.)~* Patients who have had glaucoma surgery that could effect the change in intraocular pressure (ie trabeculectomy, tube-shunts, etc.)~* Patients who are unable to assume bowing or kneeling positions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Glaucoma (Type: None): Patients with Glaucoma
- Healthy Patients (Type: None): Patients without glaucoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of an Aminoglycoside in Hemodialysis Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age upper to 18 years~* Patients hospitalized in the Service de Néphrologie - Hémodialyse, Transplantations, CHU de Limoges~* Patients requiring chronic hemodialysis~* Patients requiring a treatment by aminoglycosides~* Patients willing to give their written informed consent for their participation to the study~* Patients affiliated to the French social security system or equivalent~Exclusion Criteria:~* Patients under legal protection~* Patients unable or unwilling to provide informed consent and not under legal protection~* Patients deprived of liberty~* Contraindications to gentamicin~* Pregnant or breast-feeding women or women of childbearing potential without efficient contraception (based on declaration)~* Patients with any altered mental status or any psychiatric condition that would interfere with the understanding of the study~* Patients enrolled in another clinical trial testing drugs or therapeutic strategies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- hemodialysis patients (Type: EXPERIMENTAL): The administration of gentamicin at the beginning of the hemodialysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect Of Wound Irrigation With Irrisept™ Delivery System On Abscess Healing In Patients Presenting To The Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Immunocompetent individuals 12 years of age or older with an uncomplicated abscess~* Patient must be able to answer questions and be medically stable as defined by the Emergency Department physician~* Patient must voluntarily participate in the study~Exclusion Criteria:Patients with any of the following are excluded:~* Currently receiving antibiotics or received antibiotics within last 72 hours~* Evidence of systemic infection (fever, aches, chills, nausea)~* Requires admission to the hospital for infection or for any other reason(s)~* Abscess caused by a human or animal bite~* Prior history of hypersensitivity or allergy to Chlorhexidine Gluconate (CHG)~* Immunodeficiency (Examples: HIV Positive, Crohns Disease, Systemic Lupus Erythematosus, Addison's disease, psoriasis, splenectomy, leukemia, cancer on chemotherapy)~* Currently on any immune-modifying medication (Examples: prednisone, antivirals)~* History of chronic skin infection (3 or more in the past year)~* Chronic medical problem, for example end-stage heart, liver, kidney, or lung disease, diabetes mellitus, peripheral vascular disease, history of organ transplant~* Mental illness including but not limited to substance abuse, dementia, schizophrenia or mentally handicapped or challenged~* Incarcerated~* Patient is pregnant or thinks she may be pregnant

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IRRISEPT (Type: EXPERIMENTAL): Device containing sterile water and chlorhexidine gluconate (CHG)
- Usual Care (Type: ACTIVE_COMPARATOR): The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of a Modified Positive Airway Pressure Device to Treat Sleep Disordered Breathing

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18+~* Patients diagnosed with obesity hypoventilation syndrome (OHS) and/or obstructive sleep apnea (OSA) by a practicing sleep or respiratory physician, requiring positive airway pressure (PAP) therapy~Exclusion Criteria:~* Recent cardiac or respiratory arrest~* Gastro intestinal bleeding, ileus or recent gastrointestinal surgery~* Coma, decreased level of consciousness or agitation~* Anatomical or subjective difficulty with airway access e.g. facial surgery, trauma, vomiting upper airway obstruction~* Cerebrospinal fluid leak, abnormalities of the cribiform plate or prior history of head trauma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Positive airway pressure (PAP) device (Type: EXPERIMENTAL): Fisher \& Paykel Healthcare PAP Device. Participants will sleep overnight using themodified positive airway pressure device. Their pressures will be titrated by a qualified sleep technician, they will then be optimised during the night.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues